title: Advances in the management of follicular lymphoma.
abstract: OBJECTIVE
  Antibody-based therapy has revolutionized treatment strategies in follicular lymphoma. This review focuses on current standards and recent innovations in the management of the disease.
  
  
  RESULTS
  Understanding the mechanism of action of antibodies led to the development of next generation CD20 antibodies, antibodies targeting other molecules and bispecific antibodies. With obinutuzumab, a promising next generation of CD20 antibodies has entered phase III of clinical trials. The bispecific T-cell engager blinatumomab combines targeted therapy with immunologic activation of T cells exerting cytotoxic activity on the target cells. Apart from antibodies, small molecules targeting key pathways in lymphoma have shown promising activity in vitro and are currently in clinical development.
  
  
  CONCLUSIONS
  A wealth of new substances has entered various stages of clinical trials and has yet to show superiority over rituximab-based immunochemotherapy. Intelligent therapeutic regimens containing these drugs have to be developed. Large randomized trials comparing promising treatment options are urgently needed.
authors.affiliation: Department of Internal Medicine III, Klinikum University of Munich, Munich, Germany.
authors.forename: Till M
authors.initials: TM
authors.lastname: Seiler
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Hiddemann
mesh_terms: D018033:Antibodies, Bispecific / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D019468:Disease Management; D006801:Humans; D000077269:Lenalidomide; D008224:Lymphoma, Follicular / Q000473:pathology / Q000628:therapy*; D058990:Molecular Targeted Therapy; D000069283:Rituximab; D059039:Standard of Care; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D018033:Antibodies, Bispecific; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab; C510808:blinatumomab; D013792:Thalidomide; D000077269:Lenalidomide; C543332:obinutuzumab